Boldenone Undecylenate 300mg/ml 10x1ml Ampullen by Elbrus Pharmaceuticals

Usage

1. Confirm ampoule integrity before every injection — inspect for visible particulates, cloudiness, or seal damage; discard any compromised unit immediately.
2. Warm the ampoule to body temperature by holding it in your palm for 60–90 seconds if the oil appears viscous, which improves draw and injection flow without altering the compound.
3. Draw the full 1ml into a fresh syringe using an 18–21G draw needle; switch to a 23–25G, 1–1.5 inch injection needle to minimise post-injection site discomfort.
4. Inject intramuscularly into the gluteus medius, vastus lateralis, or deltoid using strict aseptic technique — aspirate briefly, then deliver the oil slowly over 20–30 seconds to reduce injection-site pressure.
5. Rotate injection sites across the weekly schedule; because injectable boldenone delivers near-100% bioavailability, consistency of technique matters more than compensating for absorption losses.
6. Dispose of the opened glass ampoule and used needles in a sharps container immediately after each injection; never re-use needles or attempt to store a partially drawn syringe.

Warnings

Frequently asked questions

Why does injectable boldenone undecylenate have higher bioavailability than oral boldenone?

Intramuscular injection deposits the compound directly into vascularised muscle tissue, from which it is absorbed into systemic circulation without passing through the liver first. Oral boldenone — lacking 17α-alkylation — is largely inactivated by hepatic cytochrome P450 enzymes before it reaches the bloodstream. The injectable route consistently delivers 95–99% of the administered dose into circulation; oral equivalents achieve a small fraction of that figure.

What exactly is first-pass metabolism and how does it affect boldenone taken orally?

First-pass metabolism is the hepatic enzymatic processing a drug undergoes after intestinal absorption but before it enters systemic circulation. For non-17α-alkylated steroids like boldenone, these liver enzymes oxidise and conjugate the molecule, rendering it pharmacologically inactive. Because the undecylenate ester does not confer hepatic resistance, oral dosing produces negligible plasma concentrations of active boldenone — making the injectable format the only pharmacologically effective delivery route.

How does absorption after intramuscular injection differ from what would happen if boldenone were swallowed?

After IM injection, the oil depot releases boldenone undecylenate slowly into surrounding tissue, where local esterases cleave the undecylenate chain to yield free boldenone that enters capillary blood directly. The liver only encounters this drug after it has already circulated, at which point first-pass enzymatic capacity is not concentrated in a single pass. Oral administration reverses this sequence — hepatic exposure is first, highest-concentration, and most destructive.

Why are single-dose 1ml ampoules preferable to a multi-dose vial for injectable boldenone?

Each sealed glass ampoule is a sterile, single-use unit: once opened, the entire contents are drawn and the ampoule discarded. Multi-dose vials require repeated needle punctures through a rubber septum, each of which introduces a theoretical contamination vector. For a compound injected on a weekly or twice-weekly schedule over many weeks, the cumulative sterility advantage of ten individual sealed ampoules is practically meaningful.

What are the recommended storage conditions for Elbrus Boldenone Undecylenate 10x1ml ampoules?

Store ampoules at 15–25°C in a dry location away from direct light; oil-based injectable preparations can precipitate or degrade if exposed to temperatures below 8°C or above 30°C for extended periods. Do not freeze. Inspect each ampoule visually before use — discard any unit showing particulate matter, discolouration, or a compromised seal. Once opened, the single-dose format means no partial-dose storage decisions are required. (2) angle_used

Manufacturer

Elbrus Pharmaceuticals entered the injectable anabolic market with a brand identity built on a defined geographic and commercial positioning: European-oriented distribution anchored by an Eastern European production base with access to established pharmaceutical manufacturing infrastructure. The brand's founding narrative is not centred on novelty compounds but on execution quality for established molecules — a deliberate choice reflecting the reality that the credibility gap in this product category is most often a manufacturing and testing failure, not a molecule failure. For Boldenone Undecylenate 300mg/ml specifically, Elbrus applies its standard finished-product release protocol: HPLC potency confirmation maps actual API content against the declared label concentration, and LAL endotoxin testing provides batch-level sterility evidence. The brand's commercial history reflects consistent positioning toward documented, verifiable quality claims rather than marketing-led differentiation — a stance that aligns with the increasing analytical literacy of the performance market Elbrus targets.